Last update 31 May 2025

ND-014

Overview

Basic Info

Drug Type
Single-chain FV antibody fragment
Synonyms
anti-IL-17 antibody fragment(Numab), ND-014
Target
IL-17
Action
inhibitors
Mechanism
IL-17 inhibitors(Interleukin-17 inhibitors)
Therapeutic Areas
Immune System Diseases
Active Indication-
Inactive Indication
Autoimmune Diseases
Originator Organization
Numab Therapeutics AGNumab Therapeutics AG
Active Organization-
Inactive Organization
Numab Therapeutics AGNumab Therapeutics AG
License Organization-
Drug Highest PhaseDiscontinuedDiscovery
First Approval Date-
Regulation-

Related

100 Clinical Results associated with ND-014
Login to view more data
100 Translational Medicine associated with ND-014
Login to view more data
100 Patents (Medical) associated with ND-014
Login to view more data
100 Deals associated with ND-014
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autoimmune DiseasesDiscovery
Switzerland
Numab Therapeutics AGNumab Therapeutics AG
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free